

PRESS RELEASE

Piramal Pharma Solutions Strengthens North American Capabilities with Addition of Development/Commercial Scale Roller Compactor at Sellersville, PA Site

- *Expansion features the Gerteis Macro-pactor®, known as the market leader in roller compaction technology*
- *Enhances PPS's solid oral dosage formulation capabilities in North America*

Mumbai, India | January 13, 2022: Piramal Enterprises Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that the company has added development/commercial scale roller compaction technology to its Sellersville, Pennsylvania drug product facility. The addition of the Gerteis Macro-pactor® equipment, which is designed to handle both development and commercial scale roller compaction, enhances the site's dry granulation and scale-up capabilities. Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and/or commercialization. In addition, roller compaction is an excellent technology for processing certain active pharmaceutical ingredients (APIs). The densification of dry blended powders is a critical capability that is required to handle products with poor API flow properties and instances where the API is moisture sensitive. Wet granulation is sometimes used to overcome these challenges, but many APIs are not amenable to wet granulation. In such cases, roller compaction provides a viable option to densify material and generate granules which can be further processed into capsules or tablets.

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "As part of our effort to provide comprehensive drug development and manufacturing services to customers in North America and around the world, we continually conduct internal due diligence on our capabilities. After the acquisition of our Sellersville site, we identified the need to enhance our dry granulation technology and moved forward with a plan to address it. It's just a small part of efforts to recognize customer needs around the world and provide timely solutions."

The Gerteis Macro-pactor is a versatile piece of equipment, with the ability to handle 100-300 gram batches for small scale development as well as larger volumes when used in continuous mode. Based on customer feedback

and acceptance, it is recognized as an excellent solution for both small scale development requiring roller compaction technology and larger scale clinical and commercial batches as the compounds move forward in the development cycle.

About Piramal Pharma Solutions:

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.

For more information please visit: www.piramalpharmasolutions.com | [Twitter](#) | [LinkedIn](#)

About Piramal Pharma Ltd.

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network over 100 countries. PPL includes: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business, selling over-the counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovator and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received growth equity investment from the Carlyle Group.

For more information visit: www.piramal.com | [Facebook](#) | [Twitter](#) | [LinkedIn](#)

For Media Queries:

Madiha Vahid
Corporate Communications
Madiha.Vahid@piramal.com

For Investors

Hitesh Dhaddha/Mayank Kumar

Investor Relations

investor.relations@piramal.com

